Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Rhesus monkey babies born to mothers who had the flu while pregnant had smaller brains and showed other brain changes similar to those observed in human patients with schizophrenia, a study at the University of Wisconsin-Madison in collaboration with the University of North Carolina at Chapel Hill has found.

12 Mar 2010

Children with chronic illness more likely to develop H1N1 influenza: Study

As critical care professionals develop a better understanding of the progression of H1N1, they are becoming better prepared to treat children with severe cases, according to a new study that will be published in the March issue of Pediatric Critical Care Medicine (PCCM).

12 Mar 2010

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

12 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

WHO welcomes Gates Foundation support in advancing global vaccine efforts

WHO welcomes the Bill & Melinda Gates Foundation pledge of US$ 10 billion over the next ten years to accelerate global vaccine efforts.

12 Mar 2010

HTDS receives Registration Certificate for MEVAC-Vari vaccine in Guatemala

Hard to Treat Diseases and its subsidiary Mellow Hope announce that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala.

12 Mar 2010

Obama makes impassioned argument for health reform, tough measures to combat health fraud

A shirt-sleeved President Barack Obama took his closing arguments for health care reform to the St. Louis area Wednesday.

12 Mar 2010

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

11 Mar 2010

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.

11 Mar 2010

Response Biomedical's 2009 total revenues up 69%

Response Biomedical Corporation reported that it recorded total revenues of $9,946,269, an increase of 69% compared to $5,876,337 in 2008. Clinical products revenue for the year ended December 31, 2009 increased 85% to $6,828,651 compared to $3,683,706 in 2008.

11 Mar 2010

Melexis, ProximaRF join forces to enable fast, easy development of Data Logging applications

Melexis, an early and innovative semiconductor player in the RFID market, and ProximaRF, a provider of versatile HF reader solutions, join their forces to enable fast and easy development of Data Logging applications.

11 Mar 2010

Fewer injections to treat neutropenia in childhood cancer patients

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

11 Mar 2010

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

The manufacturers of Fentanyl Transdermal Systems, in collaboration with Health Canada, would like to inform Canadians of important new changes made to the Dose Conversion Guidelines in the Product Monograph. These guidelines are used to help determine what dosage of Fentanyl Transdermal Systems is appropriate for each individual patient.

11 Mar 2010

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.

10 Mar 2010

Strong, local leadership is the key for success of health departments and activities

The surge of funds for bioterrorism preparedness over the past decade does not appear to be improving local public health resources in general, according to research from Purdue University.

10 Mar 2010

Inadvertent exposure of hospital housekeepers to drug-resistant "Superbugs" may lead to hospital-infection epidemic

One cause of the rampant international hospital-infection epidemic may be the "inadvertent exposure" of hospital housekeepers and transporters to antibiotic-resistant "Superbugs" such as MRSA, says TeleTracking Technologies CEO Anthony Sanzo.

10 Mar 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Children with chronic illness more likely to develop H1N1 influenza: Study

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

WHO welcomes Gates Foundation support in advancing global vaccine efforts

HTDS receives Registration Certificate for MEVAC-Vari vaccine in Guatemala

Obama makes impassioned argument for health reform, tough measures to combat health fraud

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Response Biomedical's 2009 total revenues up 69%

Melexis, ProximaRF join forces to enable fast, easy development of Data Logging applications

Fewer injections to treat neutropenia in childhood cancer patients

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Strong, local leadership is the key for success of health departments and activities

Inadvertent exposure of hospital housekeepers to drug-resistant "Superbugs" may lead to hospital-infection epidemic

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in